BATOROVA, Angelika, Ana BOBAN, Melen BRINZA, Toshiko LISSITCHKOV, Laszlo NEMES, Irena Zupan PRELOŽNIK, Petr SMEJKAL, Nadezhda ZOZULYA a Jerzy WINDYGA. Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A. Journal of Medicine and Life. Bucharest: Carol Davila University Press, 2022, roč. 15, č. 4, s. 570-578. ISSN 1844-122X. Dostupné z: https://dx.doi.org/10.25122/jml-2022-0103.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A
Autoři BATOROVA, Angelika, Ana BOBAN, Melen BRINZA, Toshiko LISSITCHKOV, Laszlo NEMES, Irena Zupan PRELOŽNIK, Petr SMEJKAL (203 Česká republika, domácí), Nadezhda ZOZULYA a Jerzy WINDYGA (garant).
Vydání Journal of Medicine and Life, Bucharest, Carol Davila University Press, 2022, 1844-122X.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30205 Hematology
Stát vydavatele Rumunsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Kód RIV RIV/00216224:14110/22:00128517
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.25122/jml-2022-0103
Klíčová slova anglicky hemophilia; extended half-life; prophylaxis
Štítky rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 3. 2. 2023 09:02.
Anotace
The next frontier in hemophilia A management has arrived. However, questions remain regarding the broader applicability of new and emerging hemophilia A therapies, such as the long-term safety and efficacy of non-factor therapies and optimal regimens for individual patients. With an ever-evolving clinical landscape, it is imperative for physicians to understand how available and future hemophilia A therapies could potentially be integrated into real-life clinical practice to improve patient outcomes. Against this background, nine hemophilia experts from Central European countries participated in a pre-advisory board meeting survey. The survey comprised 11 multiple-choice questions about current treatment practices and future factor and non-factor replacement therapies. The survey questions were developed to reflect current unmet needs in hemophilia management reflected in the literature. The experts also took part in a follow-up advisory board meeting to discuss the most important unmet needs for hemophilia management as well as the pre-meeting survey results. All experts highlighted the challenge of maintaining optimal trough levels with prophylaxis as their most pressing concern. Targeting trough levels of ≥30–50 IU/L or even higher to achieve less bleeding was highlighted as their preferred strategy. However, the experts had an equal opinion on how this could be achieved (i.e., more efficacious non-factor therapies or factor therapy offering broader personalization possibilities such as targeting trough levels to individual pharmacokinetic data). In summary, our study favors personalized prophylaxis to individual pharmacokinetic data rather than a “one-size-fits-all” approach to hemophilia A management to maintain optimal trough levels for individual patients.
VytisknoutZobrazeno: 4. 10. 2024 23:02